

Ellen Dittberner, AroCell's CFO, will be taking parental leave, and Lars Jakobsson will step in as the interim CFO.

Ellen Dittberner will be on parental leave from her position as Chief Financial Officer (CFO) at AroCell AB starting on February 1, 2024. During this period, Lars Jakobsson will serve as the acting CFO. Lars has previously held the position of CFO at IDL Biotech and AroCell AB from 2017 to 2022.

Contacts

Anders Hultman, CEO
Phone: +46 (0) 8 799 67 50
E-mail: anders.hultman@arocell.com

About AroCell

AroCell AB (publ) is a Swedish company that develops and markets blood and urine sample tests. The corporation specializes in oncology and bacteriology. The company has a broad product portfolio, used in healthcare, and established in various markets. In oncology, AroCell uses various biomarkers, TK1, and cytokeratins, to support the treatment of various cancers such as breast, prostate, and bladder cancers. AroCell's product portfolio also includes a rapid bacteriological test for a simple and safe diagnosis of typhoid fever. AroCell (AROC) is listed on Nasdaq First North Growth Market with Redeye AB as company's Certified Adviser. For more information; www.arocell.com

Attachments

[Ellen Dittberner, AroCell's CFO, will be taking parental leave, and Lars Jakobsson will step in as the interim CFO.](#)